Cidara Therapeutics, Inc.

CDTX XNAS • BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

Short interest (Dec 31)

6.0%

Net Short (Jan 06 ): -0.1%

Borrow Fee

0.66%

Available Shares

Price Chart

Company Overview

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

CIK: 0001610618

Asset Type: CS

Market Data

Market Cap: $6,961,583,222

Employees: 73

Status: Active

Short Interest

Current Borrow Fee 0.66%

Range: 0.66% - 0.66%

Available Shares 0

Range: 0 - 0

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime